Andrew Jack

Balancing Big Pharma's books

With patents running out on their big earning products and recent scandals undermining their image, drug companies are under pressure. Andrew Jack reports on their problems

Letting the sunshine in on doctor-pharma relationships

Drug companies are increasingly obliged to publish details of payments to doctors. The United States is leading the charge, but are we getting the full story in Europe? Andrew Jack reports

Which way now for the Cancer Drugs Fund

The government has extended the Cancer Drugs Fund for a further two years and increased its budget. Andrew Jack explains how it works and why it is controversial

Why the panic? South Korea’s MERS response questioned

Andrew Jack reports from Seoul on how government secrecy, poor infection control, and a lack of preparedness allowed the latest MERS outbreak to spark panic in South Korea

Tamiflu: “a nice little earner”

Is the story of oseltamivir, and similar antiviral drugs, a classic one of big pharma greed? Andrew Jack finds a more nuanced reality

Flu’s unexpected bonus

With over 96 countries stockpiling oseltamivir, Andrew Jack assesses who has benefited from pandemic flu

Pfizer steps up battle to defend control of pregabalin

Pfizer’s actions over its biggest blockbuster drug sparks confusion

The problem with flu vaccines

With the number of cases of swine flu continuing to rise, Andrew Jack assesses our capability to produce enough vaccine to cope with a pandemic

Can anyone stop the illegal sale of medicines online

Demand for and supply of unlicensed drugs online continues to grow despite regulators’ constant attempts to crack down on illegal activity, Andrew Jack reports

US drug firm Pfizer seeks to buy UK company AstraZeneca

Pfizer, the US pharmaceutical giant whose drugs include atorvastatin (Lipitor) and sildenafil (Viagra), is seeking to buy the UK drug firm AstraZeneca for £52bn (€63bn;